Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regulus Therapeutics (RGLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the nomination of RGLS5579 as...

RGLS : 0.99 (unch)
Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the preliminary results of a...

RGLS : 0.99 (unch)
Research Report Identifies Advanced Energy Industries, Altair Engineering, Rambus, Regulus Therapeutics, NN, and Halcon Resources with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Advanced Energy Industries,...

AEIS : 51.16 (+0.87%)
HK : 1.89 (+5.00%)
NNBR : 10.35 (+0.58%)
ALTR : 34.64 (+1.41%)
RMBS : 10.15 (+0.50%)
RGLS : 0.99 (unch)
Regulus Presents Preclinical Survival Data Highlighting Potential of Novel Treatment for Glioblastoma Multiforme

Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it presented new data on...

RGLS : 0.99 (unch)
Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates

Regulus (RGLS) delivered earnings and revenue surprises of 24.36% and -10.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

RGLS : 0.99 (unch)
Regulus Reports Third Quarter 2018 Financial Results and Recent Updates

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the third...

RGLS : 0.99 (unch)
Regulus Announces Successful Restructuring of Sanofi Collaboration

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has amended and restructured...

RGLS : 0.99 (unch)
Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RGLS : 0.99 (unch)
Regulus to Present Data from ATHENA, a Global Natural History of Disease Study for Alport Syndrome, at ASN's Kidney Week 2018

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it will present data from...

RGLS : 0.99 (unch)
Traders Get Bullish on Shares of Regulus Therapeu, Shares Up 36.6% (RGLS)

Regulus Therapeu (NASDAQ:RGLS) is one of today's best performing low-priced stocks, up 36.6% to $2.50 on 2.5x average daily volume. Thus far today, Regulus Therapeu has traded 1.3 million shares, vs....

RGLS : 0.99 (unch)
Regulus to Present Preclinical Data Supporting RGLS4326 as a Novel Therapeutic in Development for Autosomal Dominant Polycystic Kidney Disease at ASN's Kidney Week 2018

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it will present preclinical...

RGLS : 0.99 (unch)
Regulus Regains Compliance with NASDAQ Listing Requirements

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it received notice from...

RGLS : 0.99 (unch)
Research Report Identifies Oxford Immunotec Global, Ascena Retail Group, Groupon, Epizyme, Regulus Therapeutics, and B Communications with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oxford Immunotec Global PLC...

BCOM : 4.56 (-1.94%)
OXFD : 16.89 (+9.53%)
GRPN : 3.49 (-2.51%)
RGLS : 0.99 (unch)
ASNA : 2.25 (-0.44%)
EPZM : 12.89 (+3.37%)
Report: Developing Opportunities within Regulus Therapeutics, Airgain, Michael Kors, Heritage Insurance, CDK Global, and MedEquities Realty Trust -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Regulus Therapeutics Inc. (NASDAQ:RGLS),...

AIRG : 11.88 (+13.25%)
KORS : 37.92 (+1.99%)
RGLS : 0.99 (unch)
CDK : 58.19 (+1.59%)
HRTG : 14.76 (+1.79%)
MRT : 10.80 (-0.37%)
Regulus Reports First Quarter 2018 Financial Results and Pipeline Progress

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the first quarter...

RGLS : 0.99 (unch)
Regulus Initiates Multiple Ascending Dose Study in Healthy Volunteers of RGLS4326 for the Treatment of ADPKD

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has initiated a Phase I...

RGLS : 0.99 (unch)
Kathryn J. Collier Joins Regulus Board of Directors

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced Kathryn J. Collier has joined the...

RGLS : 0.99 (unch)
Regulus to Present at the Needham Healthcare Conference

Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan, President and Chief...

RGLS : 0.99 (unch)
Quotidian Technical Highlights on Selected Biotech Stocks -- Portola Pharma, Protalix BioTherapeutics, Radius Health, and Regulus Therapeutics

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on PTLA, PLX, RDUS, and RGLS which can be accessed for free by signing up to www.wallstequities.com/registration....

RDUS : 18.29 (+3.45%)
RGLS : 0.99 (unch)
PTLA : 30.96 (+3.86%)

Van Meerten Stock Picks

SecureWorks - Pick of the Day
My Stock Pick of the Day belongs to the security software company SecureWorks (SCWX).
SCWX -0.33
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar